Skip to content

Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer

Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01885754
Enrollment
56
Registered
2013-06-25
Start date
2013-02-28
Completion date
2017-10-31
Last updated
2017-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small-cell Lung Cancer

Keywords

Biopsy, Maximal incremental cardiopulmonary test, Muscle strength test, magnetic stimulation

Brief summary

Rationale: With 1.6 million new cases diagnosed each year and 1.3 million deaths, lung cancer is the leading cancer-related death worldwide and it represents a pressing health issue. Patients with lung cancer are more likely to experience cachexia, a severe debilitating disorder causing fatigue, weight loss, muscle wasting and associated with reduced physical function, increased chemotherapy toxicity and reduced survival. This syndrome occurring in about 80% of advanced cancer patients is the direct cause of death in about 20% of cases. However, despite the importance of cachexia in lung cancer, its mechanisms ans its relation with muscle function and effort tolerance are still unknown. Aim: To explore muscle function, signaling pathways and its relationship to impaired functional capacity of patients with non-small-cell lung cancer(NSCLC); depending of whether they have cachexic state at diagnosis. Methods: This study will be conducted at the Institut universitaire de cardiologie et de pneumologie de Québec. 56 patients newly diagnosed of NSCLC will be recruited and separated whether or not they have a cachexic state. The evaluation will need two visits separated by 5 days. During the evaluation the following tests will be done: * Anthropometric measures * Level of daily physical activity * Pulmonary function test * Maximal incremental cardiopulmonary exercise test on ergocycle * Endurance test on ergocycle * Muscle function tests * Magnetic stimulation * Quadriceps biopsy

Interventions

None listed

Sponsors

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women with a primary lung cancer diagnosis

Exclusion criteria

* Already have undertaken surgery, chemotherapy or radiotherapy treatment * Having an other cancer in the last five years * Taking anticoagulation therapy

Design outcomes

Primary

MeasureTime frame
Maximal quadriceps strength1 day (at the time of the diagnosis before any treatment)

Secondary

MeasureTime frame
Exercise capacity1 day (at the time of the diagnosis before any treatment)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026